Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

Salah-Eddin Al-Batran,Claudia Pauligk,Ralf Hofheinz,Sylvie Lorenzen,Andreas Wicki,Alexander Rheinhard Siebenhuener,Michael Schenk,Manfred Welslau,Vera Heuer,Eray Goekkurt,Harald Schmalenberg,Peter C. Thuss-Patience,Lisa Waberer,Jonathan Talbot,Thorsten Oliver Goetze,Nils Homann

Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma: DANTE, a randomized, open-label phase II trial of the German Gastric Group of the AIO and the SAKK.

2019

Salah-Eddin Al-Batran
Claudia Pauligk
Ralf Hofheinz
Sylvie Lorenzen
Andreas Wicki
Alexander Rheinhard Siebenhuener
Michael Schenk
Manfred Welslau
Vera Heuer
Eray Goekkurt
Harald Schmalenberg
Peter C. Thuss-Patience
Lisa Waberer
Jonathan Talbot
Thorsten Oliver Goetze
Nils Homann

TPS4142Background: Perioperative FLOT chemotherapy has become a standard of care for locally advanced, resectable gastric cancer and adenocarcinoma of the GEJ. However, patient outcomes are still u...

Keywords:

Oncology
Pathology
Adenocarcinoma
Atezolizumab
Internal medicine
Perioperative
Medicine
German
standard of care
in patient
Cancer
Physical therapy
open label
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations